Genentech | GenomeWeb

Genentech

At the Personalized Medicine World Conference, stakeholders and the former FDA commissioner discussed how regulation can advance personalized medicine amid political uncertainty.

The FDA-approved complementary assay "can provide insight into the survival benefit that may be achieved" with the treatment, Roche said.

The update includes several key initiatives such as a liquid biopsy database, a DoD-led longitudinal study, and NCI cloud collaborations with Amazon and Microsoft.

The two partners hope to start a Phase I combination trial pairing Genentech's anti-PDL1 cancer immunotherapy Tecentriq with vaccines developed using BioNTech's IVAC Mutanome. 

The deal will leverage BioNTech's IVAC Mutanome platform, which uses next-generation sequencing to identify targets for personalized mRNA-based vaccines.

The recent failure of Bristol-Myers Squibb's lung cancer immunotherapy to meet its primary endpoint demonstrates the challenge of working with imperfect biomarkers.

MiR-371-3p diminished tolerance to targeted cancer treatment in cell lines and mice, while tolerant cells had enhanced levels of genes regulated by miR-371-3p.

The protocol is currently being used to study Tecentriq and Cotellic in children, but Genentech wants to use it to evaluate drugs across its oncology portfolio.

Researchers identified 22 plasma metabolites in cancer patients that showed time- and dose-dependent changes upon treatment with the PI3K inhibitor pictilisib.

Data from the meeting suggest that lung cancer patients with ALK-positive tumors may soon have two first-line options and more choices when their disease progresses.

Pages

The White House has created a list of cuts, including to the NIH, that could be in a budget bill for this year.

The US National Institutes of Health is to allow applicants to cite preprints just as they would any other research paper, ScienceInsider reports.

Two manuscript pages handwritten by Charles Darwin are going on the auction block, according to the Los Angeles Times.

In PNAS this week: tool to track transcriptome-wide binding, evidence of balancing selection on behavior-linked genes, and more.